ARTA
SEEL

A.R.T. Advisors’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

A.R.T. Advisors’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-18
Closed -$63K – 1802
2019
Q3 		$63K Buy
18
+4
+29% +$24.1K ﹤0.01% 1301
2019
Q2 		$115K Buy
14
+11
+367% +$116K 0.01% 1177
2019
Q1 		$37K Buy
+3
New +$48.5K ﹤0.01% 1236
2017
Q3 		– Hold
0
– -$44K – 1731
2017
Q2 		– Hold
0
– – – 1316
2017
Q1 		– Hold
0
– -$19K – 1767
2016
Q4 		– Hold
0
– – – 1246

Other funds holding SEEL

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

A.R.T. Advisors's SEEL Position: Q4 2019 in Review

A.R.T. Advisors sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2019, closing a stake of 18 shares — an estimated $63K sold.

A.R.T. Advisors first reported a position in SEEL in Q1 2019 and held it in 3 quarters. The position peaked at $115K in Q2 2019. 13 funds tracked by Wall St. Rank hold SEEL as of Q4 2019.

  • A.R.T. Advisors reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 18 Seelos Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $63K.
  • A.R.T. Advisors first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2019 and held it in 3 quarters.
  • A.R.T. Advisors's Seelos Therapeutics, Inc. Common Stock position peaked at $115K in Q2 2019.
  • 13 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.